Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Abeprazan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | GPR183 | P32249 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abeprazan SCHEMBL18196939 | 0.93 | HTR6 (0.39) | HTR6FABP4FABP5MAPTDRD2 | |
| Abeprazan SCHEMBL29443418 | 0.93 | HTR6 (0.39) | HTR6FABP4FABP5MAPTDRD2 | |
| Abeprazan SCHEMBL29719476 | 0.93 | HTR6 (0.39) | HTR6FABP4FABP5MAPTDRD2 | |
| Abeprazan SCHEMBL19385601 | 0.92 | FABP4 (0.38) | HTR6FABP4FABP5MAPTDRD2 | |
| Abeprazan SCHEMBL29201776 | 0.92 | HTR6 (0.38) | HTR6FABP4FABP5MAPTDRD2 | |
| Abeprazan SCHEMBL19385615 | 0.92 | HTR6 (0.40) | HTR6FABP4FABP5MAPTDRD2 | |
| Abeprazan SCHEMBL19385623 | 0.91 | FABP4 (0.37) | HTR6FABP4FABP5MAPTDRD2 | |
| Abeprazan SCHEMBL29201783 | 0.91 | FABP4 (0.37) | HTR6FABP4FABP5MAPTDRD2 | |
| Abeprazan SCHEMBL29201774 | 0.90 | HTR6 (0.37) | HTR6FABP4FABP5MAPTDRD2 | |
| SCHEMBL18190937 | 0.87 | HTR6 (0.35) | HTR6FABP4FABP5DRD2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889545-B2 | Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-01-12 | — | — | US | claimed |
| EP-3433233-B1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE SALT | DAE WOONG PHARMA (KR) | 2020-07-22 | — | — | EP | claimed |
| US-20200123106-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-04-23 | — | — | US | claimed |
| US-20190322622-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-10-24 | — | — | US | claimed |
| US-20190047953-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-02-14 | — | — | US | claimed |
| US-11858894-B2 | Crystalline form of 1-(5-(2,4-Difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-n-methylmethanamine salt | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20230159454-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-11459297-B2 | Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2022-10-04 | — | — | US | disclosed |
| US-20210139424-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-05-13 | — | — | US | disclosed |
| US-10913715-B2 | Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-02-09 | — | — | US | disclosed |
| US-10889545-B2 | Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-01-12 | — | — | US | disclosed |
| EP-3433233-B1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE SALT | DAE WOONG PHARMA (KR) | 2020-07-22 | — | — | EP | disclosed |
| US-20190322622-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-10-24 | — | — | US | disclosed |
| US-10336695-B2 | Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-07-02 | — | — | US | disclosed |
| US-20190047953-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-02-14 | — | — | US | disclosed |
| US-20190031609-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-01-31 | — | — | US | disclosed |
| EP-3433233-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE SALT | Daewoong Pharmaceutical Co., Ltd. (KR) | 2019-01-30 | — | — | EP | disclosed |
| EP-3433232-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE | Daewoong Pharmaceutical Co., Ltd. (KR) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017164575-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE | DAEWOONG PHARMACEUTICAL CO.,LTD. (KR) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017164576-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-L-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913715-B2 | Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt | FIS1, FH, SUCNR1 | HTR6 2469/4885FABP4 2272/4885FABP5 810/4885 |
| US-20190047953-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | FH, FIS1, SUCNR1 | HTR6 2561/4885FABP4 1764/4885FABP5 686/4885 |
| US-10336695-B2 | Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt | FIS1, FH, SUCNR1 | HTR6 2469/4885FABP4 2272/4885FABP5 810/4885 |
| US-20210139424-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | FH, FIS1, SUCNR1 | HTR6 2561/4885FABP4 1764/4885FABP5 686/4885 |
| US-20190322622-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | FH, FIS1, SUCNR1 | HTR6 2561/4885FABP4 1764/4885FABP5 686/4885 |
| US-11459297-B2 | Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt | FIS1, FH, SUCNR1 | HTR6 2469/4885FABP4 2272/4885FABP5 810/4885 |
| US-10889545-B2 | Crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine salt | FIS1, FH, SUCNR1 | HTR6 2469/4885FABP4 2272/4885FABP5 810/4885 |
| US-20200123106-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | FH, FIS1, SUCNR1 | HTR6 2561/4885FABP4 1764/4885FABP5 686/4885 |
| US-20230159454-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | FH, FIS1, SUCNR1 | HTR6 2561/4885FABP4 1764/4885FABP5 686/4885 |
| US-11858894-B2 | Crystalline form of 1-(5-(2,4-Difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-n-methylmethanamine salt | FIS1, FH, SUCNR1 | HTR6 2469/4885FABP4 2272/4885FABP5 810/4885 |
| US-20190031609-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | PGA5, MIF, JUN | HTR6 2116/4885FABP4 2769/4885FABP5 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.